Nasdaq Stockholm AB: Asarina Pharma AB (publ) receives observation status

On July 18, 2024, Asarina Pharma AB (publ) (the "Company") issued a press
release with information that the Company intends to propose that an
extraordinary general meeting resolves that the Company shall enter into
voluntary liquidation. The press release also stated that the board intends to
apply for a delisting of the Company's shares from Nasdaq First North Growth
Market, provided that the general meeting resolves in accordance with the
proposal. 

The rules of First North Growth Market state that a listed company can be given
observation status if the issuer has disclosed its intention to enter into
liquidation or delist its shares from Nasdaq First North Growth Market. 

With reference to the above, Nasdaq Stockholm AB decides that the shares in
Asarina Pharma AB (publ) (ASAP, ISIN code SE0011641794, order book ID 160270)
shall be given observation status. 

For further information about this exchange notice please contact Enforcement &
Investigations, telephone [phone]. 



Nasdaq Stockholm AB